Thus, we speculated that elevated TRAF6 expression in CD19 + B cells is involved in the pathogenesis of MG through the CD40-TRAF6 signaling pathway through which it regulates the activation of the NF-κB and MAPK signaling pathways. This evidence concerns the gene NFKB1 and myasthenia gravis.